Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu
  • quotes

  • charts

  • technicals

  • company

Aequus Pharmaceuticals Inc (AQSZF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1150 +42.70%
on 09/18/17
0.1641 unch
on 09/21/17
+0.0321 (+24.32%)
since 08/21/17
3-Month
0.1150 +42.70%
on 09/18/17
0.1900 -13.63%
on 08/07/17
-0.0109 (-6.23%)
since 06/21/17
52-Week
0.1150 +42.70%
on 09/18/17
0.3491 -52.99%
on 03/02/17
-0.0773 (-32.02%)
since 09/21/16

Most Recent Stories

More News
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

VANCOUVER, BC--(Marketwired - September 07, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

VANCOUVER, BC--(Marketwired - September 07, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
Aequus Provides Second Quarter 2017 Operational Highlights

VANCOUVER, BC--(Marketwired - August 29, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
Aequus Provides Second Quarter 2017 Operational Highlights

VANCOUVER, BC--(Marketwired - August 29, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
EHVVF : 0.0700 (-12.50%)
Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
EHVVF : 0.0700 (-12.50%)
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - August 24, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
CORI : 10.83 (+1.31%)
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - August 24, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing,...

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
CORI : 10.83 (+1.31%)
Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000

VANCOUVER, BC--(Marketwired - August 16, 2017) -

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)
Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000

VANCOUVER, BC--(Marketwired - August 16, 2017) -

AQS.VN : 0.200 (+8.11%)
AQSZF : 0.1641 (+17.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Support & Resistance

2nd Resistance Point 0.1708
1st Resistance Point 0.1674
Last Price 0.1641
1st Support Level 0.1574
2nd Support Level 0.1508

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.